Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

Vitara RX vs Evernow

Two GLP-1 deals, scored on the same six factors. Vitara RX lands a Value Score of 91, Evernow a 68. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

Vitara RX

#4 · Grade A · Best Value

Est. first month

$99/mo

Save ~93% vs brand-name
Get this deal Full Vitara RX review →
VS

Evernow

#276 · Grade C · Watch List

Est. first month

From $49/mo (medication billed separately, brand-name)

Get this deal Full Evernow review →

The verdict

Better value: Vitara RX

Vitara RX takes it on Value Score, 91 to 68 an est. $99/mo first month, with no teaser step-up baked in. Evernow isn't out of it: Shoppers who want women wanting insurance-covered branded GLP-1 weight loss alongside menopause and HRT care.

Our #1 overall:Neither of these is our top pick — that's CoreAge Rx (Value Score 93).See why →

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealVitara RXEvernow
Value Score91 (A)68 (C)
Est. first month$99/moFrom $49/mo (medication billed separately, brand-name)
Save vs brand-name~93%
Semaglutide$99/moNot disclosed
Tirzepatide$149/moNot disclosed
Both moleculesYesNo
PricingFlat — no step-upWatch
Coverage49 statesCoverage not published

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

96
Lowest Real Price
90
Vitara RX: 96. Evernow: 90.
90
No Teaser-Rate Bait
60
Vitara RX: 90. Evernow: 60.
88
Nationwide Availability
45
Vitara RX: 88. Evernow: 45.
92
Both Molecules
45
Vitara RX: 92. Evernow: 45.
95
Easy Cancellation
58
Vitara RX: 95. Evernow: 58.
67
Reputation
75
Vitara RX: 67. Evernow: 75.

Vitara RX

VitaraRx is a direct-to-consumer telehealth marketplace offering compounded semaglutide and tirzepatide at flat per-drug pricing across all doses — no membership or hidden fees.

Why it's a deal

  • Among the lowest flat pricing in the market — $99/mo semaglutide and $149/mo tirzepatide, all doses same price
  • Names its 503A pharmacy partner (Manifest Pharmacy, Greer SC) — strong supply-chain transparency
  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • Covers 49 states with an explicit state list, not vague "most states" language

The fine print

  • No corporate legal entity disclosed — only the trade name "VitaraRx"
  • No named medical director — all clinical decisions made by independent providers (marketplace model)
  • All sales final — no medication returns
  • Per-vial mg quantity isn't clearly disclosed, making price comparisons harder
  • Doesn't ship to Alaska

Evernow

Evernow is a women's-focused, menopause-centered telehealth platform that prescribes branded GLP-1 weight loss medications including Ozempic, Wegovy, Zepbound, and Mounjaro via US-licensed clinicians.

Why it's a deal

  • Prescribes FDA-approved branded GLP-1s, not compounded
  • Accepts insurance for video visits (BCBS, Anthem, UnitedHealthcare, Aetna)
  • Integrates GLP-1 weight loss with menopause and HRT care
  • Flexible one-time visit or low-cost membership models

The fine print

  • Weight loss is one vertical alongside menopause and HRT care
  • GLP-1 medication cost depends on insurance and is not posted
  • State availability not specified on the site
Get the Vitara RX deal Get the Evernow deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores Vitara RX is ranked on the Vitara RX alternatives board, and the same list for the other side is on alternatives to Evernow.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.